To elucidate the clinical and histopathological features associated with autoantibodies to the signal recognition particle (SRP), we have studied 23 Japanese patients with this specificity among 3,500 patients with polymyositis/dermatomyositis and other connective tissue diseases. Anti-SRP antibodies were determined based on analysis of RNA and protein components by immunoprecipitation assays. The pathological analysis was performed by using special stainings including alkaline phosphatase, myosin ATPase, and modified Gomori trichrome stainings. Twenty-one (92%) of these 23 patients had myositis, 8 of whom (38%) required cytotoxic agents or intravenous immunoglobulin therapy in addition to corticosteroid therapy. Four patients (16%) had rheumatoid arthritis, two of whom had no features of myositis. Muscle biopsy specimens of 11 patients were examined histologically in detail. All 11 had muscle fiber necrosis and/or regeneration, but only one had infiltration of inflammatory cells. Six of the 11 (55%) patients showed type I fiber predominance by ATPase staining, while eight control myositis patients without anti-SRP antibodies did not. There was no correlation of other neurogenic features in histology with the presence of anti-SRP antibodies. These studies suggest that anti-SRP autoantibodies are most likely to be related to myopathies that are resistant to corticosteroid therapy and without inflammation histopathologically.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10165-008-0139-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful treatment of anti-signal recognition particle antibody-positive myositis with intravenous cyclophosphamide: A case report.
Fukushima J Med Sci
December 2024
Department of Rheumatology, Fukushima Medical University School of Medicine.
Myositis-specific autoantibodies play an important role on the disease phenotype of idiopathic inflammatory myopathies (IIMs). Anti-signal recognition particle (SRP) antibody-positive patients with IIMs may present with severe myopathy and highly elevated serum creatine kinase levels. These patients are often resistant to immunosuppressive therapy, but there is no established treatment strategy.
View Article and Find Full Text PDFAnti-SRP Antibodies and Myocarditis in Systemic Sclerosis Overlap Syndrome with Immune-Mediated Necrotizing Myositis (IMNM).
Medicina (Kaunas)
October 2024
Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Article Synopsis
- - Overlap syndrome of systemic sclerosis and idiopathic inflammatory myopathies is becoming more common, but its link with immune-mediated necrotizing myositis is not well-documented, requiring careful differentiation for proper treatment and prognosis.
- - Anti-signal recognition particle (anti-SRP) antibodies are crucial in diagnosing immune-mediated necrotizing myopathy, causing muscle damage and weakness, while their relationship with cardiac issues remains inconclusive, complicating potential management.
- - Diagnosing heart complications like myocarditis in these patients is challenging, often relying on cardiac imaging rather than biopsies, and this paper explores the issues of accurately diagnosing and treating diseases related to collagen and anti-SRP antibodies.
Comprehensive Enteroviral Serology Links Infection and Anti-Melanoma Differentiation-Associated Protein 5 Dermatomyositis.
ACR Open Rheumatol
January 2025
Johns Hopkins University School of Medicine, Baltimore, Maryland.
Objective: Idiopathic inflammatory myopathies (IIMs) are a group of heterogeneous, systemic autoimmune diseases characterized by specific clinical features and, frequently, skeletal muscle inflammation. Specific subtypes of IIMs can be characterized by myositis-specific autoantibodies and are associated with distinct clinical phenotypes. Here, we focus on anti-melanoma differentiation-associated protein 5 (MDA5)-positive myositis and anti-signal recognition particle (SRP)-positive myositis, both of which exhibit seasonality but lack known environmental triggers.
View Article and Find Full Text PDFTreatment of refractory immune-mediated necrotizing myopathy with efgartigimod.
Front Immunol
November 2024
Department of Neurology, Peking University First Hospital, Beijing, China.
Objective: We aimed to explore the efficacy and safety of efgartigimod in patients with refractory immune-mediated necrotizing myopathy (IMNM).
Methods: This open-label pilot observational study included seven patients with refractory IMNM, all of whom received intravenous efgartigimod treatment. The clinical response was assessed after 4 weeks of efgartigimod treatment according to the 2016 American College of Rheumatology-European League Against Rheumatism response criteria for adult idiopathic inflammatory myopathy.
Overlap of Sjögren's Syndrome and Immune-Mediated Necrotizing Myopathy With Interstitial Lung Disease: A Case Report.
Cureus
September 2024
Department of Respiratory Medicine, Fukuchiyama City Hospital, Kyoto, JPN.
Immune-mediated necrotizing myopathy (IMNM), an inflammatory muscle disease, typically presents as severe muscle weakness due to immunologic mechanisms. Some cases also show cutaneous manifestations, interstitial lung disease, and sicca symptoms. In this report, we present a unique case of an elderly man with a history of mild and stable Sjögren's syndrome (SS) for over 10 years, who later developed interstitial lung disease and myositis, leading to a diagnosis of IMNM confirmed by the presence of anti-signal recognition particle antibodies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!